Table 2 Summary of adverse events incidence, grade and duration by dose level

Cytokine Release Syndrome (CRS)

 Any grade

0

1

3

4 (33.3)

  Grade 1/2

0

1

2

3 (25.0)

  Grade ≥ 3

0

0

1

1 (8.3)

 Time to onset, days (range)

-

11

2

6.5 (2–11)

 Time from onset to resolution, days (range)

-

1

1

1 (1–1)

Immune Cell Associated Neurotoxicity Syndrome (ICANS)

 Any grade

1

1

1

3 (25.0)

  Grade 1/2

0

1

1

2 (16.7)

  Grade ≥ 3

1

0

0

1 (8.3)

 Time to onset, days (range)

12

12

8

12 (8–12)

 Time from onset to resolution, days (range)

6

2

3

3 (2–6)

Other Adverse Events AE):

 Total Patients with Grade ≥ 3 AE

4

1

2

7 (58.3)

  Neutropenia

4

1

2

7 (58.3)

  Anemia

3

0

1

4 (33.3)

  Thrombocytopenia

1

0

1

2 (16.7)

  Infection

1

0

1

2 (16.7)

 vAnorexia

0

0

1

1 (8.3)

  Diarrhea

0

0

1

1 (8.3)

  COVID-19

0

1

0

1 (8.3)

  Hypokalemia

0

0

1

1 (8.3)

  Pneumonia

1

0

0

1 (8.3)

  Sepsis

0

0

1

1 (8.3)